Reported Earnings • May 23
First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.066 loss in 1Q 2025) First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.066 loss in 1Q 2025). Revenue: CA$7.95m (up 45% from 1Q 2025). Net loss: CA$406.0k (loss narrowed 42% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Announcement • May 22
Medicure Inc. to Report Q1, 2026 Results on May 21, 2026 Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026 Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director James Kinley was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Mar 10
Medicure Inc., Annual General Meeting, May 21, 2026 Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada Announcement • Nov 14
Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025 Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025 Announcement • Aug 19
Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025 Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025 Announcement • Apr 23
Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025 Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025 Announcement • Mar 12
Medicure Inc., Annual General Meeting, May 21, 2025 Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada Announcement • Nov 22
Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors Medicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024. Announcement • Nov 19
Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024 Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023) Second quarter 2024 results: CA$0.12 loss per share (down from CA$0.024 profit in 2Q 2023). Revenue: CA$5.17m (down 14% from 2Q 2023). Net loss: CA$1.22m (down CA$1.47m from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 05
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.5% to €0.69. The fair value is estimated to be €0.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Announcement • May 30
Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director Medicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board. Reported Earnings • May 29
First quarter 2024 earnings released First quarter 2024 results: Revenue: CA$5.69m (up 1.2% from 1Q 2023). Net income: CA$51.0k (down 82% from 1Q 2023). Profit margin: 0.9% (down from 5.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • May 29
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to €0.66. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • May 04
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to €0.66. The fair value is estimated to be €0.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company became loss making. Announcement • Apr 21
Medicure Inc., Annual General Meeting, May 28, 2024 Medicure Inc., Annual General Meeting, May 28, 2024. Reported Earnings • Apr 13
Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022) Full year 2023 results: CA$0.088 loss per share (down from CA$0.13 profit in FY 2022). Revenue: CA$21.7m (down 5.9% from FY 2022). Net loss: CA$922.0k (down 168% from profit in FY 2022). Products in clinical trials Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Apr 05
Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024 Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024 Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €1.01, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 39x in the Biotechs industry in Europe. Total returns to shareholders of 10% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to €1.06, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 39x in the Biotechs industry in Europe. Total returns to shareholders of 106% over the past three years. Announcement • Nov 24
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease Medicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application. Reported Earnings • Nov 23
Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022) Third quarter 2023 results: EPS: CA$0.01 (down from CA$0.11 in 3Q 2022). Revenue: CA$5.00m (down 5.4% from 3Q 2022). Net income: CA$84.0k (down 93% from 3Q 2022). Profit margin: 1.7% (down from 21% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to €1.10, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 34x in the Biotechs industry in Europe. Total returns to shareholders of 88% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €1.06, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past three years. Reported Earnings • Jul 30
Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022) Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.067 loss in 2Q 2022). Revenue: CA$5.99m (up 4.3% from 2Q 2022). Net income: CA$253.0k (up CA$936.0k from 2Q 2022). Profit margin: 4.2% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Jul 25
Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023 Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023 Reported Earnings • May 28
First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022) First quarter 2023 results: EPS: CA$0.03 (down from CA$0.047 in 1Q 2022). Revenue: CA$5.63m (down 1.5% from 1Q 2022). Net income: CA$290.0k (down 40% from 1Q 2022). Profit margin: 5.2% (down from 8.4% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 08
Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021) Full year 2022 results: EPS: CA$0.13 (up from CA$0.071 loss in FY 2021). Revenue: CA$23.1m (up 6.1% from FY 2021). Net income: CA$1.37m (up CA$2.09m from FY 2021). Profit margin: 5.9% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Feb 02
Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors Medicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004. Reported Earnings • Nov 25
Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021) Third quarter 2022 results: EPS: CA$0.11 (up from CA$0.092 loss in 3Q 2021). Revenue: CA$5.29m (up 7.5% from 3Q 2021). Net income: CA$1.11m (up CA$2.06m from 3Q 2021). Profit margin: 21% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021) Second quarter 2022 results: CA$0.067 loss per share (down from CA$0.062 loss in 2Q 2021). Revenue: CA$5.75m (up 13% from 2Q 2021). Net loss: CA$683.0k (loss widened 6.9% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 16% share price gain to €1.01, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 71% over the past three years. Reported Earnings • Jun 01
First quarter 2022 earnings released First quarter 2022 results: Revenue: CA$5.72m (up 16% from 1Q 2021). Net income: CA$482.0k (up CA$1.53m from 1Q 2021). Profit margin: 8.4% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 29
Full year 2021 earnings released: CA$0.07 loss per share (vs CA$0.64 loss in FY 2020) Full year 2021 results: CA$0.07 loss per share (up from CA$0.64 loss in FY 2020). Revenue: CA$21.7m (up 87% from FY 2020). Net loss: CA$727.0k (loss narrowed 89% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 23
Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Third quarter 2021 results: CA$0.09 loss per share (up from CA$0.098 loss in 3Q 2020). Revenue: CA$4.92m (up 39% from 3Q 2020). Net loss: CA$946.0k (loss narrowed 9.6% from 3Q 2020). Revenue missed analyst estimates by 46%. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 44% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 28
Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$5.09m (up 90% from 2Q 2020). Net loss: CA$639.0k (down CA$658.0k from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 33 percentage points per year, which is a significant difference in performance. Executive Departure • May 18
CFO & Secretary has left the company On the 15th of May, James Kinley's tenure in the role of CFO & Secretary ended. As of December 2020, James personally held only 47.10k shares (€34k worth at the time). James is the only executive to leave the company over the last 12 months. Reported Earnings • May 12
First quarter 2021 earnings released The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$4.94m (up 64% from 1Q 2020). Net loss: CA$1.05m (loss narrowed 28% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 24
Full year 2020 earnings released The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$11.6m (down 42% from FY 2019). Net loss: CA$6.85m (loss narrowed 65% from FY 2019). Is New 90 Day High Low • Feb 05
New 90-day high: €1.10 The company is up 95% from its price of €0.56 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 09
New 90-day high: €0.88 The company is up 56% from its price of €0.56 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 19
New 90-day high: €0.69 The company is up 9.0% from its price of €0.63 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. Is New 90 Day High Low • Nov 19
New 90-day low: €0.49 The company is down 28% from its price of €0.68 on 21 August 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period. Is New 90 Day High Low • Nov 03
New 90-day low: €0.51 The company is down 24% from its price of €0.67 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. Is New 90 Day High Low • Sep 23
New 90-day low: €0.59 The company is down 5.0% from its price of €0.62 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.